Forecast

The analysts' average price target is +24,02€ (+251,68%). The median is +24,02€ (+251,68%).

Buy	5
Hold	7
Sell	2

News Go to news feed

FibroGen announces name change to Kyntra Bio, stock rises

FibroGen announces it will change its name to Kyntra Bio; the stock rose about 5% following the news. Starting January 8, 2026, the common stock will trade under the NASDAQ symbol KYNB. The company plans to focus on oncology and rare diseases, with an emphasis on the assets FG-3246 (CD46 antibody–drug conjugate) and the PET imaging agent FG-3180. Roxadustat received FDA orphan-drug designation for myelodysplastic syndromes; topline results for FG-3246 plus enzalutamide are expected in Q1 2026, and interim results from the Phase 2 monotherapy are expected in H2 2026. » More on de.investing.com
FibroGen: FDA grants roxadustat orphan-drug status for MDS

The FDA has granted roxadustat from FibroGen orphan-drug status for the treatment of myelodysplastic syndromes (MDS), which can provide financial incentives and up to seven years of market exclusivity upon approval. FibroGen is finalizing a protocol for a phase‑3 study to be filed with the FDA in Q4 2025. The company reports a current ratio of 3.71; Q3 2025 revenue rose to $1.1 million, operating expenses fell significantly, but a net loss from continuing operations of $13.1 million remained. » More on de.investing.com
FibroGen: analysts expect smaller loss but sharply lower revenue in the latest quarter

FibroGen will report results for the quarter ended 30.09.2025 on 10.11.2025. Two analysts on average forecast earnings per share of -4.007 USD (an improvement of 5.72% versus -4.250 USD in the year-ago quarter) and revenue of around 2.4 million USD, a decline of about 94.8% from 46.3 million USD a year earlier. For the fiscal year the two analysts on average expect a loss per share of -4.170 USD and revenue of about 10.0 million USD (prior year 29.6 million USD). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, FibroGen has already paid 0,26€ in dividends. The last payout was in March 2022.

Financials

In the last quarter, FibroGen had revenue of −1.29m€ and net profit of 10.49m€

(EUR)	Jun 2026	YoY
Revenue	−1.29m	212,93%
Gross profit	0.00	100,00%
Net profit	+10.49m	262,65%
EBITDA	−15.40m	57,21%

Fundamentals

Metric	Value
Market capitalization	+31.48m€
Number of shares	4.05m
52-week high/low	+18,83€ - +4,16€
Dividends	No
Beta	0,77
P/E ratio	+0,14
PEG ratio	0,00
P/B ratio	−1,07
P/S ratio	+7,00

Company profile

FibroGen, Inc. ist ein biopharmazeutisches Unternehmen, das Therapeutika zur Behandlung von schwerwiegenden, ungedeckten medizinischen Bedürfnissen erforscht, entwickelt und vermarktet. Das Unternehmen entwickelt Roxadustat, einen oralen niedermolekularen Inhibitor von Hypoxia Inducible Factor Prolyl-Hydroxylasen, der die klinische Entwicklung der Phase III für die Behandlung von Anämie bei chronischen Nierenerkrankungen in den USA, Europa, China und Japan abgeschlossen hat und sich in China in der Phase II/III für Anämie im Zusammenhang mit myelodysplastischen Syndromen befindet. Das Unternehmen entwickelt außerdem Pamrevlumab, einen humanen monoklonalen Antikörper, der die Aktivität des Bindegewebswachstumsfaktors hemmt und sich in Phase III der klinischen Entwicklung für die Behandlung von idiopathischer Lungenfibrose, Bauchspeicheldrüsenkrebs, Leberfibrose und diabetischer Nierenerkrankung sowie in einer Phase-III-Studie für die Behandlung von Duchenne-Muskeldystrophie befindet. Das Unternehmen hat Kooperationsvereinbarungen mit Astellas Pharma Inc. und AstraZeneca AB. FibroGen, Inc. wurde 1993 gegründet und hat seinen Hauptsitz in San Francisco, Kalifornien.